Filing Flows › Ironwood Pharmaceuticals (IRWD) › Guidance history
Ironwood Pharmaceuticals (IRWD) guidance history: what it guided and what it reported
Ironwood Pharmaceuticals gave guidance in 3 earnings releases on file since May 7, 2026. Its releases raised guidance twice and lowered it 0 times.
Revenue
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $450M–$475M (May 7, 2026) → reaffirmed $450M–$475M (Aug 6, 2026) → raised $460M–$485M (Nov 5, 2026) | — | to be reported | — |
Adjusted revenue
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $460M–$485M (Aug 6, 2026) → raised $485M–$510M (Nov 5, 2026) | — | to be reported | — |
Adjusted EBITDA
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $300M (May 7, 2026) → raised $310M (Aug 6, 2026) → raised $350M (Nov 5, 2026) | — | to be reported | — |
The latest quarter
Ironwood Pharmaceuticals, Q3 2026: revenue $133M (+9% year over year), operating margin 70.0%, net earnings $59.8M, operating cash flow $67.4M. The chart follows the revenue to costs, profit and cash.
Questions
Does Ironwood Pharmaceuticals beat its guidance?
Ironwood Pharmaceuticals gave guidance in 3 earnings releases on file since May 7, 2026. Its releases raised guidance twice and lowered it 0 times.
How often does Ironwood Pharmaceuticals raise guidance?
Its earnings releases raised guidance twice and lowered it 0 times since May 7, 2026.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.